CymaBay Therapeutics, Inc.
(NASDAQ : CBAY)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen, Inc. 0.26%243.921.5%$881.36m
MRNAModerna, Inc. 4.31%149.000.0%$805.56m
VRTXVertex Pharmaceuticals, Inc. 0.77%283.951.9%$483.51m
GILDGilead Sciences, Inc. 0.07%61.851.0%$475.71m
REGNRegeneron Pharmaceuticals, Inc. 0.00%591.142.6%$471.67m
NVAXNovavax, Inc. 8.46%55.7875.7%$432.23m
ILMNIllumina, Inc. 2.49%188.953.3%$344.22m
SNSSSunesis Pharmaceuticals, Inc. -5.41%3.670.7%$256.55m
BIIBBiogen, Inc. 1.67%207.341.8%$242.04m
BNTXBioNTech SE 4.27%155.460.0%$195.14m
CRSPCRISPR Therapeutics AG 2.57%62.330.6%$164.20m
BMRNBioMarin Pharmaceutical, Inc. 1.12%83.804.2%$117.49m
EXASEXACT Sciences Corp. 2.97%40.5617.7%$93.63m
IOVAIovance Biotherapeutics, Inc. 2.72%11.340.0%$90.50m
TECHBio-Techne Corp. 0.56%348.584.5%$90.12m

Company Profile

CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline includes Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA.